UK-based Motif Bio (LSE: MTFB) has announced positive top-line results from a Phase III clinical trial of its investigational drug candidate iclaprim.
Iclaprim, which was originally developed by Swiss firm Arpida, was acquired by Motif in 2015, and is being developed to treat patients with acute bacterial skin and skin structure infections (ABSSSI).
A bid for regulatory approval was turned down by the US Food and Drug Administration in 2009.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze